Pharmaceuticals company Sanofi Consumer Healthcare India announced Q2CY26 results Financial Highlights: Revenue from Operations for Q2CY26 stood at Rs 2,357 million, reflecting a YoY growth of 6.70% compared to Rs 2,209 million in Q2CY25 and a QoQ increase of 2.84% from Rs 2,292 million in Q1CY26. For H1CY26, the revenue was Rs 4,649 million compared to Rs 3,935 million in H1FY25, a growth of 18.14%. Total Income reached Rs 2,420 million in Q2CY26, marking a YoY increase of 6.84% from Rs 2,265 million in Q2CY25 and a QoQ increase of 3.07% from Rs 2,348 million in Q1CY26. Profit Before Tax (PBT) for Q2CY26 was reported at Rs 919 million, showing a YoY growth of 16.48% from Rs 789 million in Q2CY25 and a QoQ growth of 1.32% from Rs 907 million in Q1CY26. For H1CY26, PBT stood at Rs 1,826 million, up 25.33% YoY. Net Profit (Profit for the period) in Q2CY26 was Rs 688 million, representing a YoY growth of 13.34% compared to Rs 607 million in Q2CY25 and a QoQ increase of 1.47% from Rs 678 million in Q1CY26. For H1CY26, net profit reached Rs 1,366 million, a growth of 23.39% YoY. Total Comprehensive Income for Q2CY26 was Rs 688 million, up 13.34% YoY from Rs 607 million in Q2CY25 and up 1.47% QoQ from Rs 678 million in Q1CY26. Earnings Per Share (EPS) for Q2CY26 stood at Rs 29.87, compared to Rs 26.36 in Q2CY25 and Rs 29.44 in Q1CY26. Business Highlights: Domestic and Export Sales Performance: In Q2CY26, domestic sales grew by 12% YoY, aided by product relaunches. Conversely, export sales declined by 9% YoY, attributed to a high base in the previous year. Half-Year Performance: For H1CY26, domestic sales grew by 14% and export sales grew by 27% (on a low base). Product Portfolio: The Company’s portfolio encompasses Allergy, Digestive Wellness, Pain Care, and Multivitamins, with key brands including Allegra, DePURA, Avil, and Combiflam. Impact of Product Relaunches: The results were influenced by the successful relaunch of Combiflam Suspension and Allegra Suspension in Q2CY25 and Depura Kids in Q3CY25, following a voluntary recall in 2024. Demerger and Independence: Sanofi Consumer Healthcare India Limited (SCHIL) emerged as a distinct legal entity following its demerger from Sanofi India Limited on June 1, 2024, and now operates independently in the Consumer Healthcare sector. Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India, said: “Our performance this quarter reflects the disciplined execution on all fronts. Our targeted investments behind our brands and go-to-market capabilities are translating into profitable growth and market share gains in most of our brands, reinforcing our confidence in the strength of our strategy.” Result PDF